Anavar vs Primobolan: Which Is Safer for Women?

Oxandrolone (Anavar) and methenolone (Primobolan) are the two compounds most often discussed as "women's" anabolic steroids. Both are DHT-family androgens with relatively mild androgenic ratings on paper. Both have decades of use in female athletes and physique competitors. They are not equivalent, however, and the choice between them comes down to four practical questions: route, hepatic load, lipid impact, and sourcing reliability.

Anavar (oxandrolone) is an oral 17-alpha-alkylated DHT derivative. The 2-oxa-17-alpha-methyl structure gives it the highest oral bioavailability of any AAS (about 97 percent) and a unique pharmacological feature: roughly 28 percent of an oral dose is excreted unchanged by the kidneys, which moderates hepatic exposure compared to other 17-AA orals. Its signature pharmacological effect is aggressive SHBG suppression (70 to 90 percent at typical female doses).

Primobolan (methenolone) comes in two forms: methenolone acetate (oral) and methenolone enanthate (injectable). The injectable enanthate is overwhelmingly the more commonly used form because the oral acetate has poor bioavailability and requires high doses. The methenolone molecule itself is not 17-alpha-alkylated in its injectable enanthate form, which is why it has minimal hepatic load compared to anavar. The androgenic rating is lower than anavar's and SHBG suppression is modest.

The choice between the two is dominated by route, sourcing, and how aggressive the goal is. The literature comparing them head-to-head in women is essentially nonexistent.

Route and hepatic load:

• Anavar: oral, 17-alpha-alkylated, mild but real hepatic stress. ALT typically rises 1.5 to 3x ULN at female doses, with peak at weeks 4 to 6. About 28 percent renal clearance moderates the hepatic exposure compared to other 17-AA orals.
• Primobolan injectable: no 17-alpha-alkylation, minimal hepatic load. ALT rarely moves meaningfully. The oral acetate form is mildly hepatotoxic but is not the form most users run.

SHBG suppression:

• Anavar: 70 to 90 percent suppression at 10 to 20 mg/day. This is the signature pharmacological feature and the reason free testosterone amplifies disproportionately.
• Primobolan: modest, typically 30 to 50 percent at standard female doses (50 to 100 mg/week injectable).

Lipid impact:

• Anavar: 20 to 45 percent HDL crash at 10 to 20 mg/day, with HDL2 subfraction preferentially depleted. ApoB rises 30 to 40 percent. Recovery within 4 to 12 weeks off cycle.
• Primobolan: 10 to 20 percent HDL crash at typical doses, the gentlest of the AAS commonly used by women on lipids. Recovery within 4 to 8 weeks.

Virilization risk:

• Both are DHT family compounds and carry voice change, clitoral hypertrophy, hair loss, and body hair risk.
• Anavar's risk profile is amplified by the aggressive SHBG suppression which spikes free testosterone disproportionately.
• Primobolan's risk profile is mechanistically lower per mg, but injectable doses tend to be higher (50 to 100 mg/week vs anavar 10 to 20 mg/day) which partially offsets the per-mg advantage.

HPG axis suppression:

• Anavar: meaningful suppression at 10 to 20 mg/day, often produces missed periods within 4 to 8 weeks. Recovery 2 to 6 months.
• Primobolan: gentler HPG suppression. Some women maintain regular cycles on low-dose primo. Recovery typically faster.

Sourcing and cost:

• Anavar: widely available, expensive but easier to find authentic product. UGL anavar is sometimes dianabol or winstrol mislabeled; lab testing helps.
• Primobolan: notoriously faked. Most "primo" on the black market is testosterone enanthate, masteron, or boldenone in a labeled vial. Authentic primo is expensive and supply is unreliable. Sourcing risk is the single biggest practical disadvantage.

Detection time (for tested athletes):

• Anavar: about 3 weeks
• Primobolan acetate (oral): 4 to 5 weeks
• Primobolan enanthate (injectable): up to 5 weeks, sometimes longer

Joint feel:

• Both can produce mild joint dryness from suppressed estradiol if HPG axis is shut down. Neither is notorious for joint pain at female doses.

Choose anavar if:

• You want oral convenience and no injections
• You're prepared to manage the hepatic load (TUDCA 250 to 500 mg/day, baseline plus week 4 LFTs)
• You can accept the HDL crash and have a plan for lipid monitoring (HDL, ApoB, omega-3s, possible bergamot)
• Sourcing authentic primo locally is unreliable

Choose primobolan if:

• You can find an authentic injectable source (this is the biggest hurdle)
• You're prepared to manage twice-weekly intramuscular or subcutaneous injections
• You want the gentlest lipid and hepatic profile available among AAS for women
• You're planning a longer cycle (8 to 12 weeks) where cumulative hepatic load matters
• You want to minimize HPG-axis suppression so periods are more likely to continue

Choose neither if:

• You haven't yet run baseline bloodwork (lipid panel, LFTs, SHBG, free T, DHT, LH/FSH, estradiol, progesterone)
• You don't have a plan for stopping if virilization markers cross threshold
• You're hoping for "side effect free" gains. Both produce real androgen receptor activation and real virilization risk; the question is magnitude, not presence.

Starting doses in women:

• Anavar: 5 to 10 mg/day, single dose with food. Titrate to 15 to 20 mg after week 4 bloodwork if tolerated.
• Primobolan enanthate: 50 mg per week injectable, single or split dose. Titrate to 75 to 100 mg/week after week 4 bloodwork if tolerated.

Cycle length 6 to 8 weeks is the standard for both at female doses. Past 8 weeks the cumulative virilization risk rises sharply without proportional gains.